文献速递临床试验与 GCP组学、生物样本库与精准医学基础与转化研究

HER2阳性炎性乳腺癌HER2阻断期间的克隆演化分析:阿法替尼联合或不联合长春瑞滨的II期开放标签临床试验

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
PubMed 文献 · PLoS Med · 2016-12-06

该开放标签、单臂II期试验纳入HER2阳性炎性乳腺癌患者,评估阿法替尼单药及联合长春瑞滨的疗效与安全性,并进行外显子分析。阿法替尼单药治疗26例中9例(35%)获临床获益;疾病进展后联合长春瑞滨的10例中,经曲妥珠单抗治疗者4例中2例、未治疗者6例中0例获临床获益。研究因LUX-Breast 1试验结果提前终止。

要点

  • 阿法替尼单药在未接受曲妥珠单抗的HER2阳性炎性乳腺癌患者中显示活性(19例中9例临床获益)。
  • HER2阳性炎性乳腺癌具有更高的突变负荷、频发TP53功能获得性突变及11q13.5扩增重叠PAK1。
  • PI3K/Akt信号通路体细胞激活与未接受曲妥珠单抗患者更短的无进展生存期相关(p=0.03)。

核心结论

  • 阿法替尼联合或不联合长春瑞滨在预设亚组分析中,对未接受曲妥珠单抗的HER2阳性炎性乳腺癌患者显示出活性。
  • HER2阳性炎性乳腺癌以频发TP53功能获得性突变和高突变负荷为特征。
  • 与HER2阳性炎性乳腺癌相关的高突变负荷提示检查点抑制剂治疗可能在该疾病中发挥作用。

研究设计与样本

  • 开放标签、单臂II期临床试验(ClinicalTrials.gov NCT01325428),纳入HER2阳性炎性乳腺癌患者。
  • 患者接受阿法替尼40 mg每日一次直至进展,此后接受阿法替尼40 mg每日一次联合静脉长春瑞滨25 mg/m2每周一次。
  • 主要终点为临床获益;次要终点为客观缓解(OR)、OR持续时间及无进展生存期(PFS)。
  • 试验包括阿法替尼单药治疗前后前瞻性计划的外显子分析。
  • 因LUX-Breast 1试验结果,试验招募提前终止。

主要发现

  • 阿法替尼单药治疗26例患者中,9例(35%)获临床获益;经曲妥珠单抗治疗者7例中0例,未接受曲妥珠单抗者19例中9例获临床获益。
  • 疾病进展后,10例接受阿法替尼联合长春瑞滨,经曲妥珠单抗治疗者4例中2例、未治疗者6例中0例获临床获益。
  • 所有患者均发生治疗相关不良事件(AEs)。
  • 与TCGA HER2阳性非炎性乳腺癌队列相比,HER2阳性炎性乳腺癌患者的突变负荷和新抗原负荷显著更高,TP53功能获得性突变更频繁,并存在重叠PAK1的复发性11q13.5扩增。
  • 预设探索性分析显示,未接受曲妥珠单抗且肿瘤携带PI3K/Akt信号通路体细胞激活的患者,与无此激活者相比,PFS显著更短(p=0.03)。

关键数值与推荐

  • 阿法替尼单药:40 mg每日一次,直至疾病进展。
  • 阿法替尼联合长春瑞滨:阿法替尼40 mg每日一次,静脉长春瑞滨25 mg/m2每周一次。
  • 主要终点临床获益:阿法替尼单药治疗26例中9例(35%)获临床获益。
  • PI3K/Akt通路体细胞激活与未接受曲妥珠单抗患者更短PFS相关(p=0.03)。
  • LUX-Breast 1试验显示阿法替尼联合长春瑞滨与曲妥珠单抗联合长春瑞滨相比,PFS和OR率相似,但总生存期(OS)更短且耐受性更差。

临床怎么用

  • 作者在预设亚组分析中认为,阿法替尼联合或不联合长春瑞滨在未接受曲妥珠单抗的HER2阳性炎性乳腺癌患者中显示出活性。
  • 作者认为,HER2阳性炎性乳腺癌相关的高突变负荷提示检查点抑制剂治疗可能在该疾病中发挥作用。
  • 原文未据此给出其他推荐。

局限性

  • 患者队列相对较小,结果应谨慎解读。
  • 治疗前后肿瘤活检之间可能存在肿瘤采样偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to investigate the efficacy and safety of afatinib, an irreversible ErbB family inhibitor, alone and in combination with vinorelbine in patients with HER2-positive IBC. This trial included prospectively planned exome analysis before and after afatinib monotherapy. METHODS AND FINDINGS: HER2-positive IBC patients received afatinib 40 mg daily until progression, and thereafter afatinib 40 mg daily and intravenous vinorelbine 25 mg/m2 weekly. The primary endpoint was clinical benefit; secondary endpoints were objective response (OR), duration of OR, and progression-free survival (PFS). Of 26 patients treated with afatinib monotherapy, clinical benefit was achieved in 9 patients (35%), 0 of 7 trastuzumab-treated patients and 9 of 19 trastuzumab-naïve patients. Following disease progression, 10 patients received afatinib plus vinorelbine, and clinical benefit was achieved in 2 of 4 trastuzumab-treated and 0 of 6 trastuzumab-naïve patients. All patients had treatment-related adverse events (AEs). Whole-exome sequencing of tumour biopsies taken before treatment and following disease progression on afatinib monotherapy was performed to assess the mutational landscape of IBC and evolutionary trajectories during therapy. Compared to a cohort of The Cancer Genome Atlas (TCGA) patients with HER2-positive non-IBC, HER2-positive IBC patients had significantly higher mutational and neoantigenic burden, more frequent gain-of-function TP53 mutations and a recurrent 11q13.5 amplification overlapping PAK1. Planned exploratory analysis revealed that trastuzumab-naïve patients with tumours harbouring somatic activation of PI3K/Akt signalling had significantly shorter PFS compared to those without (p = 0.03). High genomic concordance between biopsies taken before and following afatinib resistance was observed with stable clonal structures in non-responding tumours, and evidence of branched evolution in 8 of 9 tumours analysed. Recruitment to the trial was terminated early following the LUX-Breast 1 trial, which showed that afatinib combined with vinorelbine had similar PFS and OR rates to trastuzumab plus vinorelbine but shorter overall survival (OS), and was less tolerable. The main limitations of this study are that the results should be interpreted with caution given the relatively small patient cohort and the potential for tumour sampling bias between pre- and post-treatment tumour biopsies. CONCLUSIONS: Afatinib, with or without vinorelbine, showed activity in trastuzumab-naïve HER2-positive IBC patients in a planned subgroup analysis. HER2-positive IBC is characterized by frequent TP53 gain-of-function mutations and a high mutational burden. The high mutational load associated with HER2-positive IBC suggests a potential role for checkpoint inhibitor therapy in this disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT01325428.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Goh G, Schmid R, Guiver K, et al. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med. 2016. PMID: 27923043. doi:10.1371/journal.pmed.1002136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。